An observational study in Chronic Pancreatitis, sponsored by Changhai Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2025-04-15.
Sponsored by Changhai Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Pancreatitis, Chronic by Changhai Hospital — 13 open to participants now, 18 under way, none of them phase 3. Pancreatitis, Chronic · Changhai Hospital.
Among the 41 studies in Pancreatitis, Chronic by Changhai Hospital, this one is the 2nd largest by planned enrollment of the 28 observational ones that give a count, is one of 9 that started in 2025, is one of 28 observational ones, reaches primary completion later than 17 of the 17 other live ones, and was the 31st registered.
266 studies on the registry are indexed under Pancreatitis, Chronic; 76 are open to participants now.
Browse Pancreatitis, Chronic studies →13 of the 41 studies in Pancreatitis, Chronic by Changhai Hospital are open now, in 1 country. Recruiting first, the newest first:
Changhai Hospital · Sites in China
Ages 18–80
Changhai Hospital · Sites in China
Ages 18–85
Changhai Hospital · Sites in China
Ages 18–85
Changhai Hospital · Sites in China
Ages 18+
Changhai Hospital · Sites in China
Ages 18–65
By country, each count listing its studies:
Of the 49 Pancreatitis, Chronic studies recruiting now, 31 (63%) set no upper age limit and 12 (24%) stop at 75 or younger; 8 take children under 18; 11 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,000 is above the median of 300 across 117 observational studies indexed under Pancreatitis, Chronic.
Median enrollment 134 across the 13 interventional studies, 657 across the 28 observational. Of the 15 that completed or were terminated, 1 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
Changhai Hospital is the lead sponsor of 355 studies on the registry; 136 are open to participants now.
1 of the studies in Pancreatitis, Chronic by Changhai Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03324698Changhai HospitalThe Natural History of Chronic Pancreatitis | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 41 studies in Pancreatitis, Chronic by Changhai Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to establish a prospective cohort of chronic pancreatitis (CP) patients to provide evidence-based guidance for clinical practice and comprehensively optimize diagnostic and treatment strategies. The study aims to collect detailed demographic information, clinical data, medical imaging, biological samples, and follow-up information from CP patients.
Chronic pancreatitis (CP) is clinically characterized by abdominal pain and pancreatic dysfunction, including diabetes and steatorrhea, which significantly impact patients' quality of life and life expectancy. Globally, the annual incidence of CP is 9.62 per 100,000 individuals, with a mortality rate of 0.09 per 100,000 and a prevalence ranging from 13.5 to 560 per 100,000. In China, the prevalence of CP has also been increasing annually, currently reaching 13.52 per 100,000 individuals. In most countries worldwide, the incidence and prevalence of CP are generally on the rise, leading to an increasing healthcare burden. Due to the endocrine and exocrine functions of the pancreas, CP presents with highly variable clinical symptoms, diverse complications, and a risk of malignant transformation. Therefore, establishing a standardized, large-scale, long-term follow-up prospective cohort for CP is crucial for a more comprehensive understanding of its clinical characteristics and for providing high-quality evidence-based medical guidance for clinical practice.
Chronic pancreatitis patients in China.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group included all enrolled patients with CP.
Other: Observation
Based on the patient's specific clinical condition, the appropriate examination and treatment in accordance with the conventional diagnosis and treatment standards of CP will be performed, including but not limited to: CT, MRI, endoscopic ultrasound (EUS) with or without biopsy, endocrine hormone testing (such as oral glucose tolerance test or mixed meal tolerance testing), pancreatic exocrine function tests (such as fecal elastase-1 test), extracorporeal shock wave lithotripsy (ESWL), endoscopic retrograde cholangiopancreatography (ERCP), and pancreatic enzyme replacement therapy. Patients were followed up regularly.
Incidence of complications
The incidence of complications after the diagnosis of chronic pancreatitis, including diabetes mellitus, pancreatic exocrine insufficiency, pancreatic pseudocyst, biliary stricture, pancreatic portal hypertension, and pancreatic fistula.
Time frame: Annually for 10 years post-enrollment (Year 1 through Year 10)
Incidence of pancreatic cancer
The incidence of pancreatic cancer after the diagnosis of chronic pancreatitis
Time frame: 5 and 10 years after enrollment
Efficacy of endoscopic treatment
Proportion of patients with chronic pancreatitis who had pain relief after conservative, endoscopic (ESWL and ERCP), or surgical treatment
Time frame: 1 year after treatment
Scores of quality of life
Quality of life scores for patients with chronic pancreatitis are obtained using SF-36 (36-Item Short Form Health Survey) which contains 8 dimensions scored from 0 to 100 (standardized converted scores). The higher score means better function.
Time frame: Annually for 10 years post-enrollment (Year 1 through Year 10)
HbA1c level
Glycated hemoglobin (HbA1c) level measured in venous blood (unit: %).
Time frame: Baseline and Year 1 to Year 10 post-enrollment (annually)
Blood glucose profile characteristics
Blood glucose profile from mixed-meal glucose tolerance test (MMTT) and continuous glucose monitoring system (CGMS) (unit: mmol/L or mg/dL).
Time frame: Baseline and Year 1 to Year 10 post-enrollment (annually)
Pancreatic and gut hormone levels
Levels of specific pancreatic hormones (C-peptide, insulin, glucagon, etc.) and gut hormones (ghrelin, gastric inhibitory peptide, glucagon like peptide-1, etc.) measured in venous blood (unit: specify for each hormone).
Time frame: Baseline and Year 1 to Year 10 post-enrollment (annually)
Plan to share: No
Started Apr 2025 (actual). Primary completion is estimated for Dec 2035, 127 months after the start.
Of 57 non-industry observational studies under Pancreatitis, Chronic, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 160. This study's planned 127 months is above that.
Counting every sponsor, half of 59 studies reached it within 63 months; a quarter within 28 and three quarters within 160.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.